Polianta Ltd’s TG Therapeutics TGTX Stock Holding History

Polianta Ltd’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-22,900	Closed	-$1.19M	–	95
2020 Q4	$1.19M	Buy	+22,900	New	+$774K	0.66%	45

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Polianta Ltd's TGTX Position: Q1 2021 in Review

Polianta Ltd sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 22,900 shares — an estimated $1.19M sold.

Polianta Ltd first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $1.19M in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

Polianta Ltd reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
Polianta Ltd sold 22,900 TG Therapeutics shares in Q1 2021, an estimated $1.19M.
Polianta Ltd first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
Polianta Ltd's TG Therapeutics position peaked at $1.19M in Q4 2020.
240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Polianta Ltd's 13F filing for Q1 2021, filed 14 Apr 2021.